Yusheng Han Purchases 24,900 Shares of Burning Rock Biotech (NASDAQ:BNR) Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han bought 24,900 shares of the company’s stock in a transaction on Friday, June 26th. The shares were bought at an average price of $8.00 per share, for a total transaction of $199,200.00. Following the completion of the acquisition, the director directly owned 18,404,086 shares in the company, valued at approximately $147,232,688. This trade represents a 0.14% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

Yusheng Han also recently made the following trade(s):

• On Wednesday, June 24th, Yusheng Han purchased 250,000 shares of Burning Rock Biotech stock. The stock was bought at an average cost of $8.00 per share, for a total transaction of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han purchased 5,990 shares of Burning Rock Biotech stock. The stock was bought at an average price of $7.50 per share, with a total value of $44,925.00.
• On Monday, June 22nd, Yusheng Han acquired 104,650 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $7.45 per share, with a total value of $779,642.50.
• On Tuesday, June 16th, Yusheng Han acquired 111,110 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $9.00 per share, with a total value of $999,990.00.
• On Friday, June 12th, Yusheng Han acquired 210,000 shares of Burning Rock Biotech stock. The shares were bought at an average price of $9.25 per share, for a total transaction of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han acquired 24,760 shares of Burning Rock Biotech stock. The stock was bought at an average cost of $8.74 per share, for a total transaction of $216,402.40.

Burning Rock Biotech Price Performance

Shares of NASDAQ BNR opened at $9.82 on Friday. The firm has a market cap of $103.31 million, a PE ratio of -11.98 and a beta of 1.32. The company has a current ratio of 3.05, a quick ratio of 2.81 and a debt-to-equity ratio of 0.06. Burning Rock Biotech Limited Sponsored ADR has a 1-year low of $3.23 and a 1-year high of $41.72. The company has a fifty day moving average price of $12.35 and a 200 day moving average price of $19.96.

Burning Rock Biotech (NASDAQ:BNR) last released its earnings results on Tuesday, June 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.29) by $2.09. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.The firm had revenue of $15.66 million during the quarter, compared to analysts’ expectations of $19.21 million.

Analyst Ratings Changes

A number of research firms recently issued reports on BNR. Wall Street Zen downgraded Burning Rock Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Crcm LP increased its stake in Burning Rock Biotech by 13.8% in the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock valued at $1,917,000 after buying an additional 26,809 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Burning Rock Biotech during the 4th quarter worth about $220,000. Renaissance Technologies LLC boosted its stake in shares of Burning Rock Biotech by 13.8% during the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock worth $571,000 after buying an additional 4,290 shares during the last quarter. Finally, Prospera Financial Services Inc grew its holdings in shares of Burning Rock Biotech by 26.0% in the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after acquiring an additional 6,430 shares in the last quarter. Institutional investors own 30.03% of the company’s stock.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.